HIV-specific effector cytotoxic T lymphocytes and HIV-producing cells colocalize in white pulps and germinal centers from infected patients

Blood

Volumn 97, Issue 9, 2001, Pages 2695-2701

  Hosmalin, Anne ^a,b,c,d,e   Samri, Assia ^a,b,c,d,e   Dumaurier, Marie Jeanne ^a,b,c,d,e   Dudoit, Yasmine ^a,b,c,d,e   Oksenhendler, Eric ^a,b,c,d,e   Karmochkine, Marina ^a,b,c,d,e   Autran, Brigitte ^a,b,c,d,e   Wain Hobson, Simon ^a,b,c,d,e   Cheynier, Rémi ^a,b,c,d,e  

^a INSTITUT COCHIN   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSTITUT PASTEUR   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD8 ANTIGEN;

ARTICLE; CELL SUSPENSION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FLOW CYTOMETRY; GERMINAL CENTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOCOMPETENT CELL; LYMPHOID ORGAN; NUCLEIC ACID ANALYSIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD; VIRUS REPLICATION;

EID: 0035353175     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.9.2695     Document Type: Article

References (52)

1. Cheynier R, Gratton S, Halloran M, Stahmer I, Letvin NL, Wain-Hobson S. Antigenic stimulation by BCG vaccine as an in vivo driving force for SIV replication and dissemination. Nat Med. 1998;4:421-427.
2. Ostrowski M, Krakauer D, Li Y, et al. Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies. J Virol. 1998;72:7772-7784.
3. Armstrong JA, Horne R. Follicular dendritic cells and virus-like particles in AIDS-related lymphadenopathy. Lancet. 1984;ii:370-372.
4. Biberfeld P, Chayt KJ, Marselle LM, Biberfeld G, Gallo RC, Harper ME. HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy, Am J Pathol. 1986;125:436-442.
5. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 1993;362:359-362.
6. LeTourneau A, Audouin J, Diebold J, Marche C, Tricottet V, Reynes M. LAV-like particles in lymph node germinal centers in patients with the persistent lymphadenopathy syndrome and the acquired immunodeficiency syndrome-related complex: an ultrastructural study of 30 cases. Hum Pathol. 1986;17:1047-1053.
7. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993;362:355-358.
8. Tenner-Racz K, Racz P, Dietrich M, Kern P. Altered follicular dendritic cells and virus-like particles in AIDS and AIDS-related lymphadenopathy. Lancet. 1985;i:105-106.
9. Prevot S, Fournier J, Tardivel I, Audouin J, Diebold J. Detection by in situ hybridization of HIV-1 RNA in spleens of HIV-1 seropositive patients with thrombocytopenic purpura, Pathol Res Pract. 1989;185:187-193.
10. Emilie D, Peuchmaur M, Maillott M, et al. Production of interleukins in HIV-1-replicating lymph nodes. J Clin Invest, 1990;86:148-159.
11. Fox CH,Tenner-Racz K, Racz P, Firpo A, Pizzo PA, Fauci AS. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis. 1991;164:1051-1057.
12. Hufert F, van Lunzen J, Janossy G, et al. Germinal centre CD4+ T cells are an important site of HIV replication in vivo. AIDS. 1997;11:849-857.
13. + T lymphocyte infection frequency in spleens of HIV-positive patients. J Virol. 1995;69:4737-4745.
14. Spiegel H, Herbst H, Niedobitek G, Foss H-D, Stein H. Follicular dendritic cells are a major reservoir for human immunodeficiency virus type 1 in lymphoid tissues facilitating infection of CD4+ T-helper cells. Am J Pathol. 1992;140:15-22.
15. Schmitz J, van Lunzen J, Tenner-Racz K, et al. Follicular dendritic cells retain HIV-1 particles on their plasma membrane, but are not productively infected in asymptomatic patients with follicular hyperplasia. J Immunol. 1994;153:1352-1359.
16. Delassus S, Cheynier R, Wain-Hobson S. Nonhomogeneous distribution of human immunodeficiency virus type 1 proviruses in the spleen. J Virol. 1992;66:5642-5645.
17. Cheynier R, Henrichwark S, Hadida F, et al. HIV and T-cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T-lymphocytes. Cell. 1994;78:373-387.
18. Plata F, Autran B, Martins LP, et al. AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature. 1987;328:348-351.
19. Wong J, Ignacio C, Torriani F, Havlir D, Fitch N, Richman D. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol. 1997;71:2059-2071.
20. b. Gratton S, Cheynier R, Dumaurier MJ, Oksenhendler E, Wain-Hobson S. Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers. Proc Natl Acad Sci U S A. 2000;97:14566-14571.
21. Letvin NL. Progress in the development of an HIV-1 vaccine. Science. 1998;280:1875-1880.
22. Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science. 1986;234:1563-1566.
23. Yang O, Walker B. CD8+ cells in human immunodeficiency virus type I pathogenesis: cytolytic and noncytolytic inhibition of viral replication. Adv Immunol. 1997;66:273-311.
24. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68:4650-4655.
25. Borrow P, Lewicki H, Hahn B, Shaw G, Oldstone M. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994;68:6103-6110.
26. Pantaleo G, Demarest JF, Soudeyns H, et al. Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV, Nature. 1994;370:463-467.
27. Kuroda M, Schmitz J, Charini W, et al. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J Immunol. 1999;162:5127-5133.
28. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-1170.
29. Rinaldo C, Huang X, Fan Z, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol. 1995;69:5838-5842.
30. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath J. Cytotoxic T cell responses, viral load and disease progression in early HIV-1 infection. N Engl J Med. 1997;337:1267-1274.
31. Ogg G, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA, Science, 1998;279:2103-2106.
32. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999;283:857-860.
33. Jin X, Bauer D, Tuttleton S, et al. Dramatic rise in plasma viremia after CD8+ T cell depletion in SIV-infected macaques. J Exp Med. 1999;189:991-998.
34. Matano T, Shibata R, Siemon C, Connors M, Lane H, Martin M. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol. 1998;72:164-169.
35. Racz P, Tenner-Racz K, van Vloten F, et al. Lymphatic tissue changes in AIDS and other retrovirus infections: tools and insights. Lymphology. 1990;23:85-91.
36. Tenner-Racz K, Stellbrink HJ, van Lunzen J, et al. The unenlarged lymph nodes of HIV-1 infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation: the impact of highly active antiretroviral therapy. J Exp Med. 1998;187:949-959.
37. Hadida F, Parrot A, Kieny M-P, et al. Carboxy-terminal and central regions of human immunodeficiency virus-1 NEF recognized by cytotoxic T lymphocytes from lymphoid organs. J Clin Invest. 1992;89:53-60.
38. Kuroda M, Schmitz J, Charini W, et al. Comparative analysis of cytotoxic T lymphocytes in lymph nodes and peripheral blood of SIV-infected Rhesus monkeys. J Virol. 1999;73:1573-1579.
39. Brodie S, Lewinsohn D, Patterson B, et al. In vivo migration and function of transferred HIV-1 specific cytotoxic T cells. Nat Med. 1999;5:34-41.
40. Gray C, Lawrence J, Schapiro J, et al. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol. 1999;162:1780-1788.
41. Zajac A, Blattman J, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998;188:2205-2213.
42. Ehl S, Klenerman P, Aichele P, Hengartner H, Zinkernagel R. A functional and kinetic comparison of antiviral effector and memory CTL populations in vivo and in vitro. Eur J Immunol. 1997;27:3404-3413.
43. Wong J, Gunthard H, Havlir D, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci U S A. 1997;94:12574-12579.
44. Lafeuillade A, Chollet L, Hittinger G, Profizi N, Costes O, Poggi C. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of < 200 copies/mL. J Infect Dis. 1998;177:235-238.
45. Zhang Z, Schuler T, Cavert W, et al. Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV infection. Proc Natl Acad Sci U S A. 1999;96:5169-5172.
46. Perrin L, Yerly S, Marchal F, et al. Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 infection on bitherapy. J Infect Dis. 1998;177:1497-1501.
47. Hockett R, Kilby J, Derdeyn C, et al. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med. 1999;189:1545-1554.
48. Dalod M, Harzic M, Pellegrin I, et al. Evolution of CTL responses to HIV type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy, J Infect Dis. 1998;178:61-69.
49. Carcelain G, Blanc C, Leibowitch J, et al. T cell changes after combined nucleoside analogue therapy in HIV primary infection. AIDS. 1999;13:1077-1081.
50. Kalams S, Goulder P, Shea A, et al. Levels of HIV-1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia wih highly active antiretroviral therapy. J Virol. 1999;73:6721-6728.
51. Dyrhol-Riise A, Voltersvik P, Olofson J, Asjö B. Activation of CD8 T cells normalizes and correlates with the level of provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection. AIDS. 1999;13:2365-2376.
52. Binley J, Jin X, Huang Y, et al. Persistent antibody responses but declining CTL responses to multiple HIV type 1 antigens in a long term non progressing individual with a defective p17 proviral sequence and no detectable viral RNA expression. J Virol. 1998;72:3472-3474.